Immuneel Therapeutics Raises over Rs 100 Cr in Series B

Why It Matters

The infusion equips Immuneel to scale India’s first approved CAR‑T therapy, reshaping cancer‑treatment access in emerging markets and attracting further global partnerships.

Key Takeaways

• Series B secured >Rs 100 cr ($10.5 M) from diverse investors
• Funds target GMP capacity, Qartemi rollout, and APAC/Middle East expansion
• Valuation after Series A extension stood at ~Rs 587 cr ($71 M)
• Immuneel’s Qartemi is India’s first approved CAR‑T therapy for lymphoma
• Total capital raised exceeds $40 M, underpinning robust R&D pipeline

Pulse Analysis

The Indian biotech sector has entered a new phase of capital intensity, as domestic and diaspora investors increasingly back home‑grown therapeutics. 5 million), exemplifies this trend, drawing participation from Singularity AMC, Rainmatter by Zerodha, and seasoned venture firms such as Eight Roads and F‑Prime Capital. The infusion follows a comparable Rs 100 crore Series A extension that lifted the company’s post‑money valuation to roughly Rs 587 crore ($71 million). This momentum reflects confidence in India’s ability to develop and commercialize advanced cell‑based therapies, aided by government biotech incentives and a growing talent pool that further de‑risk the investment thesis.

At the heart of Immuneel’s growth story is Qartemi, the nation’s first regulatory‑cleared CAR‑T therapy for non‑Hodgkin lymphoma and certain leukemias. By securing GMP manufacturing capacity, the firm aims to meet rising domestic demand while positioning the product for export to the Asia‑Pacific and Middle‑East markets, where access to personalized oncology treatments remains limited. The Series B proceeds will also fund the next wave of pipeline candidates, leveraging the company’s proprietary gene‑editing platform to broaden indications beyond hematologic cancers. Early clinical data have shown response rates above 70%, reinforcing the therapy’s competitive edge against foreign CAR‑T products.

The funding round sends a clear signal to global investors that Indian CAR‑T innovators can compete on both scientific and commercial fronts. With a cumulative capital base surpassing $40 million, Immuneel is poised to attract strategic co‑development partners, as evidenced by ongoing collaborations in Australia and Southeast Asia. Successful scale‑up could accelerate the region’s shift toward precision oncology, reduce reliance on imported biologics, and generate sizable returns for venture capitalists betting on next‑generation immunotherapies. If Immuneel can demonstrate cost‑effective manufacturing, it may set a benchmark for affordable CAR‑T delivery in emerging economies.